The DOI matches its Crossref record.
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
Abstract
Objective: To determine the incidence and clinical effects of antibodies that develop during treatment with natalizumab. Methods: In two randomized, double-blind, placebo-controlled studies (natalizumab safety and efficacy in relapsing remitting multiple sclerosis [MS, AFFIRM] and safety and efficacy of natalizumab in combination with interferon β-1a [INFβ1a] in patients with relapsing remitting MS [SENTINEL]) of patients with relapsing multiple sclerosis, blood samples were obtained at baseline and every 12 weeks to determine the presence of antibodies against natalizumab. Antibodies to natalizumab were measured using an ELISA. Patients were categorized as “transiently positive” if they had detectable antibodies (≥0.5 μg/mL) at a single time point or “persistently positive” if they had antibodies at two or more time points ≥6 weeks apart. Results: In the AFFIRM study, antibodies were detected in 57 of 625 (9%) of natalizumab-treated patients: Twenty (3%) were transiently positive and 37 (6%) were persistently positive. Persistently positive patients showed a loss of clinical efficacy as measured by disability progression (p ≤ 0.05), relapse rate (p = 0.009), and MRI (p ≤ 0.05) compared with antibody-negative patients. In transiently positive patients, full efficacy was achieved after approximately 6 months of treatment, the time when patients were becoming antibody negative. The incidence of infusion-related adverse events was significantly higher in persistently positive patients. Results of SENTINEL were similar to AFFIRM, except with regard to sustained disability progression; differences between persistently positive and antibody-negative patients were not statistically significant. Conclusions: The incidence of persistent antibody positivity associated with natalizumab is 6%. Reduced clinical efficacy is apparent in persistently positive patients. Patients with a suboptimal clinical response or persistent infusion-related adverse events should be considered for antibody testing. GLOSSARY: BLQ = below the limit of quantification; EDSS = Expanded Disability Status Scale; Gd+ = gadolinium enhancing; IFNβ1a = interferon β-1a; MS = multiple sclerosis; MSFC = multiple sclerosis functional composite; OD = optical density.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Shankar, G., Arkin, S., Cocea, L., Devanarayan, V., Kirshner, S., Kromminga, A., Quarmby, V., Richards, S., Schneider, C. K., Subramanyam, M., et al. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9599-2 · Cited by 353
TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
FOROOGHIAN, F., CUKRAS, C., MEYERLE, C. B., CHEW, E. Y., & WONG, W. T. (2009) · Retina · doi:10.1097/iae.0b013e3181a2c1c3 · Cited by 179
Evaluating and mitigating the immunogenicity of therapeutic proteins
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.008 · Cited by 118
Body fluid biomarkers for multiple sclerosis—the long road to clinical application
Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.173 · Cited by 106
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. W., Rudick, R. A., Stuart, W. H., Lublin, F. D., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., & Panzara, M. A.
- Venue
- Neurology
- Published
- 2007-10-02
- Volume
- 69
- Issue
- 14
- Pages
- 1391-1403
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2023211244
- Cited by
- 339
- References
- 0
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. https://app.cochat.ai/papers/10.1212/01.wnl.0000277457.17420.b5
- The paper
- Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. W., Rudick, R. A., Stuart, W. H., Lublin, F. D., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., & Panzara, M. A. (2007). The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology. https://doi.org/10.1212/01.wnl.0000277457.17420.b5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.